✦ LIBER ✦

Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents

✍ Scribed by Ko-Chung Lin; Alfredo C Castro

Book ID: 104415097
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 533 KB
Volume: 2
Category: Article
ISSN: 1367-5931
DOI: 10.1016/s1367-5931(98)80120-8

No coin nor oath required. For personal study only.

✦ Synopsis

In recent years antagonists of very late antigen-4 (VLA4, also known as integrin alpha(4) beta(1)) have shown great promise in treating inflammatory disorders in a number of animal models. The most advanced in this endeavor is a humanized anti-alpha(4) antibody, Antegren, which is in phase II clinical trials for multiple sclerosis. The first reported small-molecule VLA4 antagonist to advance into clinical trials is currently in phase I as an aerosol for treating asthma. A number of peptides, cyclic peptides and peptidomimetics have been disclosed and are in preliminary stages of development.

📜 SIMILAR VOLUMES

Potent α4β1 Peptide Antagonists as Poten

Potent α4β1 Peptide Antagonists as Potential Anti-Inflammatory Agents

✍ Jackson, David Y.; Quan, Clifford; Artis, Dean R.; Rawson, Thomas; Blackburn, Br 📂 Article 📅 1997 🏛 American Chemical Society 🌐 English ⚖ 415 KB

352 POSTER Small molecule antagonists of

352 POSTER Small molecule antagonists of very late antigen (VLA)-4 inhibit metastasis formation and tumor growth of melanoma

✍ M. Valcarcel; F. Aspichueta; R. Hernan; M. Solaun; V. Gutierrez; L. Mendoza 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 78 KB

Phosphodiesterase 4 inhibitors as novel

Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents

✍ Annette M Doherty 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 957 KB

and clinical studies of phosphodiesterase 4 inhibitors have shown that these agents may find utility in a wide range of inflammatory disorders, including asthma, chronic obstructive pulmonary disease, atopic dermatitis, rheumatoid arthritis, multiple sclerosis and various neurological disorders. The

Inhibition of eosinophilia in vivo by a

Inhibition of eosinophilia in vivo by a small molecule inhibitor of very late antigen (VLA)-4

✍ Hiromi Okigami; Keisuke Takeshita; Masaomi Tajimi; Hiroshi Komura; Markus Albers 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 501 KB

1,3,4-Trisubstituted pyrazole analogues

1,3,4-Trisubstituted pyrazole analogues as promising anti-inflammatory agents

✍ Alegaon, S.G.; Alagawadi, K.R.; Garg, M.K.; Dushyant, K.; Vinod, D. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 822 KB

4,4-Disubstituted Cyclohexylamine based

4,4-Disubstituted Cyclohexylamine based CCR5 Chemokine Receptor Antagonists as Anti-HIV-1 agents

✍ Maosheng Duan; Wieslaw Kazmierski; Christopher Aquino; Rob Ferris; Terry Kenakin 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 164 KB